Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
EGF-like, fibronectin type-III and laminin G-like domain-containing protein (EGFLAM), commonly known as pikachurin, is a highly conserved, retina-specific, extracellular matrix-like protein essential for the formation and maintenance of the photoreceptor ribbon synapse. Pikachurin is encoded by the EGFLAM gene and comprises 1,017 amino acids, containing two fibronectin type III (FN3) domains, three laminin G domains, and two EGF-like domains[1][4][5]. It acts as a dystroglycan-binding protein that bridges pre-synaptic photoreceptor dystroglycan complexes with post-synaptic GPR179 orphan receptors on bipolar cells, thereby ensuring precise synaptic alignment and effective visual signaling[1][3]. Defects in pikachurin or its binding to dystroglycan have been associated with congenital muscular dystrophies presenting with ocular symptoms, as well as other retinal synaptic dysfunctions[1][3]. Although critical to synaptic structure in the retina and linked to inherited eye diseases, pikachurin/EGFLAM is not a current direct therapeutic drug target and has no known drug interactions[1][3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on EGF-like, fibronectin type-III and laminin G-like domain-containing protein (EGFLAM).